1. Home
  2. SPRO vs EAF Comparison

SPRO vs EAF Comparison

Compare SPRO & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.24

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

N/A

Current Price

$6.57

Market Cap

198.6M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
EAF
Founded
2013
1886
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
198.6M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
SPRO
EAF
Price
$1.24
$6.57
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$11.75
AVG Volume (30 Days)
675.7K
232.7K
Earning Date
05-13-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
$504,134,000.00
Revenue This Year
N/A
$4.25
Revenue Next Year
$300.00
$12.49
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$4.92
52 Week High
$3.08
$20.32

Technical Indicators

Market Signals
Indicator
SPRO
EAF
Relative Strength Index (RSI) 38.90 43.59
Support Level $1.10 $6.16
Resistance Level $1.29 $8.21
Average True Range (ATR) 0.05 0.44
MACD 0.04 -0.13
Stochastic Oscillator 56.80 19.80

Price Performance

Historical Comparison
SPRO
EAF

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.

Share on Social Networks: